DiscGenics

Robert Wynalek, Chief Operating Officer
Salt Lake City, UT
(Private)

DiscGenics is a biotechnology company developing advanced spinal therapeutics to treat patients with diseases of the intervertebral disc. DiscGenics is the only company to utilize therapeutic progenitor cells derived from the intervertebral disc to treat the disc. The company’s allogeneic methodology allows DiscGenics to derive many doses from each adult tissue donation. The company’s first product, Injectable Discogenic Cell Therapy (IDCT), is in preclinical development for the treatment of moderate degenerative disc disease. This cellular treatment offers a cost effective and non-surgical solution to patients that currently have few treatment options. Furthermore, the treatment may delay the progression towards costly and often ineffective surgical interventions necessary at the late stages of degeneration. Follow-on products utilizing the same cell population with different scaffold carriers are being explored for additional disc-related indications.